Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Oct 13 - Oct 18
The trade-off: retatrutide produces substantially higher weight loss with a higher discontinuation rate
KnerrPJMowerySADourosJDPremdjeeBHjllundKRHeYet al
Cardiovascular diabetology , 2022, 21.1: 169
Triple Agonist vs Dual Agonist Comparison Contents Key Takeaways Two Compounds, One Manufacturer, Different Receptor Counts Weight Loss: The Numbers Side by Side Mechanism Breakdown: What the Third Receptor Adds Safety: Where the Tradeoffs Appear Evidence Quality: Phase 2 vs Phase 3 Where Each Compound Might Win The Bottom Line Explore Research Peptides Retatrutide 12mg 24.2% body weight lost (Phase 2, 48 wk) vs Tirzepatide 15mg 22.5% body weight lost (Phase 3, 72 wk) 3 vs 2 receptor targets (retatrutide vs tirzepatide) 63% vs 57% reached 20%+ weight loss (highest dose arms) Eli Lilly same manufacturer for both compounds Sources: Retatrutide Phase 2 (NEJM, 2023), SURMOUNT-1 (NEJM, 2022)
Add more vegetables, lean proteins, and whole foods to your diet
Once synthesized, the peptide must undergo lyophilization
US$ 20.03
US$ 27.95
US$ 27.38
US$ 26.56
US$ 24.59
US$ 21.15
